title: Opportunistic infections complicating solid organ transplantation with alemtuzumab induction.
abstract: Opportunistic infections remain a common complication of solid organ transplantation. Despite significant changes in immunosuppression and infectious diseases prophylaxis, data are limited on the contemporary epidemiology and outcomes of opportunistic infections. Alemtuzumab, a potent lymphocyte-depleting antibody, has been used with increased frequency in solid organ transplant recipients in the last decade. A literature review was performed to summarize the current understanding of the epidemiology, risk factors, and outcomes of opportunistic infections complicating solid organ transplantation with and without alemtuzumab induction therapy. Areas where data are limited regarding opportunistic infections in solid organ transplantation with alemtuzumab induction are indicated.
authors.affiliation: Northwestern University Transplant Outcomes Research Collaborative, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
authors.forename: M
authors.initials: M
authors.lastname: Helfrich
authors.affiliation: Northwestern University Transplant Outcomes Research Collaborative, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.|Divisions of Infectious Diseases & Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
authors.forename: M G
authors.identifier: http://orcid.org/0000-0003-3347-9671
authors.initials: MG
authors.lastname: Ison
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009894:Opportunistic Infections / Q000209:etiology / Q000276:immunology*; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000276:immunology*; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab
keywords: SOT; alemtuzumab; opportunistic infection